Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q38151672)
Watch
English
HER2 therapies and gastric cancer: a step forward.
scientific article published on October 2013
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
title
HER2 therapies and gastric cancer: a step forward
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
author
Ramon Andrade de Mello
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
Antonió Manuel Ferreira Araújo
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
author name string
Andrea Marin Marques
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
language of work or name
English
0 references
publication date
1 October 2013
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
published in
World Journal of Gastroenterology
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
volume
19
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
page(s)
6165-6169
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
issue
37
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
cites work
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Advanced HER2-positive gastric cancer: current and future targeted therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Pertuzumab in HER2-positive breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Cancer statistics, 2012
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Anti-HER agents in gastric cancer: from bench to bedside
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Trastuzumab: in HER2-positive metastatic gastric cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
The role of HER2 in cancer therapy and targeted drug delivery
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Chemotherapy for advanced gastric cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
6 September 2017
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
14 September 2017
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
23 June 2018
[Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
23 June 2018
Chylous ascites due to signet ring cell gastric adenocarcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
Prognostic significance of HER2/neu expression in gastric cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
Gastric cancer: trastuzumab trial results spur search for other targets.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787345
retrieved
31 August 2018
Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24115812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24115812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24115812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24115812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24115812
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.3748/WJG.V19.I37.6165
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
PMCID
3787345
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
PubMed ID
24115812
1 reference
stated in
Europe PubMed Central
PMCID
3787345
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24115812%20AND%20SRC:MED&resulttype=core&format=json
retrieved
27 February 2020
ResearchGate publication ID
257649610
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
